Several trials with patients with CML have already shown that in predetermined conditions (CMR for at least 2 years after ≥3 years of TKI treatment), the production of BCR::ABL1 inhibitor can be discontinued and rechallenged in the case of molecular relapse [15]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.